Form D · Pharmaceuticals
SignPath Pharma, Inc.
Sandy, UT · CIK 0001455694
Offering snapshot reported May 12, 2021 · SEC filing
- Reported sold
- $1.56M Offering amount: $11M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $6K Reported outside-investor minimum
- First sale
- Jun 1, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 12, 2021 | Initial | $1,561,000 | No comparison | 18 | SEC filing |
| Aug 28, 2020 | Initial | $525,000 | No comparison | 5 | SEC filing |
| Dec 18, 2017 | Initial | $235,000 | No comparison | 4 | SEC filing |
| Jul 15, 2016 | Initial | $245,000 | No comparison | 8 | SEC filing |
| Jan 27, 2016 | Amendment | $2,359,076 | $2,039,076vs Nov 26, 2014 | 36 | SEC filing |
| Nov 26, 2014 | Initial | $320,000 | No comparison | 3 | SEC filing |
| Jun 5, 2014 | Amendment | $4,355,500 | $3,355,500vs Mar 22, 2013 | 14 | SEC filing |
| Mar 22, 2013 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| May 4, 2012 | Amendment | $1,304,000 | $724,000vs Oct 4, 2011 | 26 | SEC filing |
| Oct 4, 2011 | Initial | $580,000 | No comparison | 9 | SEC filing |
| Jun 1, 2010 | Initial | $25,000 | No comparison | 1 | SEC filing |
| Mar 5, 2009 | Initial | $0 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-399017
The Company may pay registered broker-dealers up to 10% sales commissions.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Tim Touloukian | 2803832 |
Source: Form D, filed May 12, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Meyers Associates L.P. | Promoter |
| Meyers Associates, L.P. | Promoter |
| Arthur Ballon, Ph.D | Director, Executive |
| Arthur Bollon | Director |
| Arthur P. Bollon, Ph.D | Director |
| Beth Hecht | Director |
| Lawrence D. Helson | Director, Executive |
| Kai Larson | Director, Executive |
| Kai Larson, Jd | Executive |
| Jack Levine | Director |
| Jack Levine, Cpa | Director |
| None Meyers Associates, L.P. | Promoter |
| N/A Meyers Associates, L.P. | Promoter |
| Robert Saguso | Director |
| Robert Seguso | Director, Executive |
| Peter Sordillo | Executive |
| Timothy Toloukian | Executive |
| Timothy Touloukian | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
7984 South 1300 East
Sandy, UT, 84094
Sandy, UT, 84094